Out, out - Making amyloid's candle briefer

New England Journal of Medicine

Volumn 373, Issue 12, 2015, Pages 1167-1169

  Comenzo, Raymond L ^a  

^a TUFTS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; AMYLOID PROTEIN; SERUM AMYLOID P; CARBOXYLIC ACID; MONOCLONAL ANTIBODY; PYRROLIDINE DERIVATIVE;

AMYLOIDOSIS; DISEASE ACTIVITY; DISEASE ASSOCIATION; EDITORIAL; HUMAN; MEDICAL RESEARCH; MOLECULAR DYNAMICS; MOLECULAR PATHOLOGY; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN FUNCTION; PROTEIN METABOLISM; RISK ASSESSMENT; RISK FACTOR; ANTAGONISTS AND INHIBITORS;

AMYLOIDOSIS; ANTIBODIES, MONOCLONAL; CARBOXYLIC ACIDS; HUMANS; PYRROLIDINES; SERUM AMYLOID P-COMPONENT;

EID: 84942043676     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMe1508746     Document Type: Editorial

References (11)

1. Comenzo RL, Zhang Y, Martinez C, Osman K, Herr era GA. The tropism of organ involvement in primary systemic amyloidosis: contributions of Ig V(L) germ line gene use and clonal plasma cell burden. Blood 2001; 98: 714-20.
2. Comenzo RL, Gertz MA. Autol ogous hematopoietic cell transplantation for AL amyloidosis. In: Blume KG, Forman SF, Appelbaum FR, eds. Thomas' hematopoietic cell transplantation. 3rd ed. Malden, MA: Wiley-Blackwell, 2004: 1283-97.
3. Richards DB,Cookson LM,Berges AC,et al. Therapeutic clearance of amyloid by antibodies to serum amyloid P component N Engl J Med 2015 373 1106-14.
4. Schenk D. Treatment of Alzheimer's disease: the beginning of a new era. Curr Alzheimer Res 2006; 3: 177.
5. Diomede L, Rognoni P, Lavatelli F, et al. A Caenorhabditis elegans-based assay recognizes immunoglobulin light chains causing heart amyloidosis. Blood 2014; 123: 3543-52.
6. Jaccard A, Comenzo RL, Hari P, et al. Efficacy of bortezomib, cyclophosphamide and dexamethasone in treatment-naïve patients with high-risk cardiac AL amyl oidosis (Mayo Clinic stage III). Haematologica 2014; 99: 1479-85.
7. Gertz MA, Landau HJ, Comenzo RL, et al. Cardiac and renal biomarker responses in a phase 1/2 study of NEOD001 in patients wit h AL amyloidosis and persistent organ dysfunction. J Clin Oncol 2015; 33: Suppl. abstract.
8. Comenzo RL, Reece D, Palladini G, et al. Consensus guidelines for the conduct and reporting of clinical t rials in systemic light-chain amyloidosis. Leukemia 2012; 26: 2317-25.
9. Palladini G, Dispenzieri A, Gertz MA, et al. New criteria for response to treatment in immunoglobulin light chain amyloi dosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol 2012; 30: 4541-9.
10. Coelho T, Adams D, Silva A, et al. Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N Engl J Med 2013; 369: 819-29.
11. Weiss BM, Hebreo J, Cordaro DV, et al. Increased serum free light chains precede the presentation of immunoglobulin li ght chain amyloidosis. J Clin Oncol 2014; 32: 2699-704.